---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011953"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:58:18.930957+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reviva FY2023 net loss $39.3M; restates 2022; positive Phase 3 schizophrenia data; RECOVER-2 trial planned

## Summary
- Net loss $39.3M ($1.65/sh) for FY2023 vs restated $28.3M ($1.45/sh) for FY2022.
- Cash $23.4M as of Dec 31, 2023; completed $30M registered direct offering in Nov 2023.
- Restated FY2022 results due to ~$3.9M under-accrual of clinical trial expenses.
- Phase 3 RECOVER-1 met primary endpoint: 10.1-point PANSS reduction at 50mg vs placebo (p<0.001).
- Registrational RECOVER-2 trial starts Q2 2024; NDA submission for brilaroxazine targeted Q3 2025.

## SEC filing metadata
- accession: 0001437749-24-011953
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/rvph20240325_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011953
- JSON: https://secwatch.observer/filing/0001437749-24-011953.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011953.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the full year ended December 31, 2023 results: net income approximately $39.3 million, EPS $1.65 per share.
  - Period: the full year ended December 31, 2023
  - Net income: approximately $39.3 million
  - EPS: $1.65 per share
  - Result: reported results
  source text: For the year ended December 31, 2023, net loss was approximately $39.3 million, or $1.65 per share, compared to approximately $28.3 million, or $1.45 per share, for the year ended December 31, 2022 (as restated).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.